Relapses reduced by 67% after 72 months with ozanimod in patients with multiple sclerosis

WEST PALM BEACH, Fla. — In an open-label extension, treatment with ozanimod demonstrated sustained efficacy for disease progression in patients with relapsing multiple sclerosis, per research presented at ACTRIMS 2024.
“Given MS is progressive and irreversible in nature with no cure, it is imperative to understand patients’ long-term treatment responses to assist in the clinical decision-making process, with the goal of stopping disease progression and improving outcomes,” Jonathan Sadeh, MD, MSc, senior vice president and head of Immunology, Cardiovascular and

WEST PALM BEACH, Fla. — In an open-label extension, treatment with ozanimod demonstrated sustained efficacy for disease progression in patients with relapsing multiple sclerosis, per research presented at ACTRIMS 2024.
“Given MS is progressive and irreversible in nature with no cure, it is imperative to understand patients’ long-term treatment responses to assist in the clinical decision-making process, with the goal of stopping disease progression and improving outcomes,” Jonathan Sadeh, MD, MSc, senior vice president and head of Immunology, Cardiovascular and